IN2012CH01573A - - Google Patents
Download PDFInfo
- Publication number
- IN2012CH01573A IN2012CH01573A IN1573CH2012A IN2012CH01573A IN 2012CH01573 A IN2012CH01573 A IN 2012CH01573A IN 1573CH2012 A IN1573CH2012 A IN 1573CH2012A IN 2012CH01573 A IN2012CH01573 A IN 2012CH01573A
- Authority
- IN
- India
- Prior art keywords
- compounds
- bruton
- btk
- formula
- tyrosine kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
The present disclosure provides hetero-biclyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by Bruton’s tyrosine kinase (Btk) activity, The disclosure also relates to the process of preparation of compounds of Formula (I).These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of Bruton’s tyrosine kinase (Btk), such as inflammatory and/or autoimmune disorder, cell proliferation, rheumatoid arthritis, psoriasis, psoriatic arthritis, transplant rejection, graft-versus-host disease, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, systemic lupus, erythematosus or other disorders.
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2013/000259 WO2013157022A1 (en) | 2012-04-20 | 2013-04-18 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
EP13737672.9A EP2838898B1 (en) | 2012-04-20 | 2013-04-18 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
CN201380019452.8A CN104662018B (en) | 2012-04-20 | 2013-04-18 | Substituted Heterobicyclic compounds, composition and its medical applications |
IN1573CH2012 IN2012CH01573A (en) | 2012-04-20 | 2013-04-18 | |
CA2869954A CA2869954C (en) | 2012-04-20 | 2013-04-18 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity |
AU2013250726A AU2013250726B2 (en) | 2012-04-20 | 2013-04-18 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
JP2015506355A JP6182593B2 (en) | 2012-04-20 | 2013-04-18 | Substituted heterobicyclic compounds, compositions and medicaments and uses thereof |
US14/509,793 US9233983B2 (en) | 2012-04-20 | 2014-10-08 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
ZA2014/07341A ZA201407341B (en) | 2012-04-20 | 2014-10-09 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
IL235146A IL235146A (en) | 2012-04-20 | 2014-10-19 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1573CH2012 IN2012CH01573A (en) | 2012-04-20 | 2013-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012CH01573A true IN2012CH01573A (en) | 2015-07-10 |
Family
ID=48794150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1573CH2012 IN2012CH01573A (en) | 2012-04-20 | 2013-04-18 |
Country Status (10)
Country | Link |
---|---|
US (1) | US9233983B2 (en) |
EP (1) | EP2838898B1 (en) |
JP (1) | JP6182593B2 (en) |
CN (1) | CN104662018B (en) |
AU (1) | AU2013250726B2 (en) |
CA (1) | CA2869954C (en) |
IL (1) | IL235146A (en) |
IN (1) | IN2012CH01573A (en) |
WO (1) | WO2013157022A1 (en) |
ZA (1) | ZA201407341B (en) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011146313A1 (en) | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
BR112014007788A2 (en) | 2011-10-03 | 2017-04-18 | Univ North Carolina Chapel Hill | Pyrrolopyrimidine compounds for cancer treatment |
CN104302627A (en) | 2012-05-22 | 2015-01-21 | 北卡罗来纳大学教堂山分校 | Pyrimidine compounds for the treatment of cancer |
JP6348492B2 (en) | 2012-08-10 | 2018-06-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Heteroaromatic compounds as breton-type tyrosine kinase (BTK) inhibitors |
WO2014062774A1 (en) | 2012-10-17 | 2014-04-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
EP2925752A4 (en) | 2012-11-27 | 2016-06-01 | Univ North Carolina | Pyrimidine compounds for the treatment of cancer |
CA2905530A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
CN104211703B (en) * | 2013-05-30 | 2018-04-03 | 南京勇山生物科技有限公司 | A kind of fused heterocyclic compound as Bu Ludun kinase inhibitors |
US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
WO2015157125A1 (en) | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Therapuetic uses of selected pyrazolopyrimidine compounds with anti-mer tyrosine kinase activity |
CN105294571B (en) * | 2014-07-03 | 2019-04-23 | 浙江九洲药业股份有限公司 | One kind is according to Shandong for Buddhist nun's intermediate and its preparation method and application |
CN106661002B (en) | 2014-08-04 | 2021-06-29 | 纽韦卢森公司 | Pyrimidine derivatives for the treatment of inflammatory, metabolic, neoplastic and autoimmune diseases |
WO2016057500A1 (en) | 2014-10-06 | 2016-04-14 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
US10272070B2 (en) | 2014-10-14 | 2019-04-30 | The Board of Trustees of the Leland Stanford Junio r University | Method for treating neurodegenerative diseases |
LT3209656T (en) * | 2014-10-24 | 2020-07-27 | Bristol-Myers Squibb Company | Indole carboxamides compounds useful as kinase inhibitors |
EP3042903B1 (en) * | 2015-01-06 | 2019-08-14 | Impetis Biosciences Ltd. | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
ES2849951T3 (en) | 2015-06-18 | 2021-08-24 | 89Bio Ltd | 4-benzyl and 4-benzoyl substituted piperidine derivatives |
US9902696B2 (en) | 2015-06-18 | 2018-02-27 | Cephalon, Inc. | 1,4-substituted piperidine derivatives |
GB201517216D0 (en) * | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201517217D0 (en) * | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
HUE051771T2 (en) | 2015-12-15 | 2021-03-29 | Univ Leland Stanford Junior | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation |
EP3402789B1 (en) | 2016-01-13 | 2020-03-18 | Boehringer Ingelheim International Gmbh | Isoquinolones as btk inhibitors |
US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
AU2017250302B2 (en) | 2016-04-15 | 2021-01-21 | Blueprint Medicines Corporation | Inhibitors of activin receptor-like kinase |
CA2969295A1 (en) | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
US10266528B2 (en) * | 2016-08-16 | 2019-04-23 | Merck Patent Gmbh | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof |
KR102565546B1 (en) | 2016-11-25 | 2023-08-10 | 카나 바이오사이언스, 인코포레이션 | Novel oxoisoquinoline derivatives |
CN106883235B (en) * | 2016-12-29 | 2019-04-30 | 天津国际生物医药联合研究院 | The preparation and application of furodiazole compound |
CN110072865B (en) * | 2017-02-08 | 2022-02-11 | 中国医药研究开发中心有限公司 | Pyrrolo-aromatic heterocyclic compounds, preparation method and medical application thereof |
CN108794480A (en) * | 2017-04-28 | 2018-11-13 | 天津药物研究院有限公司 | Azolopyrimidines, preparation method and use |
US11236086B2 (en) | 2017-10-18 | 2022-02-01 | Blueprint Medicines Corporation | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase |
CA3085259A1 (en) * | 2017-12-13 | 2019-06-20 | Lupin Limited | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors |
CN109293638B (en) * | 2018-03-27 | 2020-08-14 | 大连理工大学 | Enhanced fluorescence sensor for targeted recognition of receptor tyrosine kinase and application of fluorescence imaging of cell membrane |
CN108707154A (en) * | 2018-07-10 | 2018-10-26 | 刘凤娟 | A kind of drug solvent for the treatment of cancer closes object and preparation method thereof |
KR20210068399A (en) | 2018-08-06 | 2021-06-09 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 주니어 유니버시티 | 2-Arylbenzimidazole as a PPA RGC 1 alpha activator for the treatment of neurodegenerative diseases |
EP3847170B1 (en) * | 2018-09-06 | 2022-06-22 | F. Hoffmann-La Roche AG | Novel cyclic amidine compounds for the treatment of autoimmune disease |
CN109180642A (en) * | 2018-10-04 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | Phthalazines ketone BTK inhibitor and its application |
CN109369619A (en) * | 2018-10-04 | 2019-02-22 | 南京先进生物材料与过程装备研究院有限公司 | Phthalazines ketone compound crystal form B and preparation method thereof |
CN109485636A (en) * | 2018-10-04 | 2019-03-19 | 南京先进生物材料与过程装备研究院有限公司 | A kind of hydrochloride of novel B TK kinase inhibitor and preparation method thereof and purposes |
CN109336864A (en) * | 2018-10-04 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | Phthalazines ketone compound crystal form N and preparation method thereof |
CN109293635A (en) * | 2018-10-04 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | A kind of P crystal form of novel B TK kinase inhibitor and preparation method thereof |
CN109180644A (en) * | 2018-10-04 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | A kind of mesylate of novel B TK kinase inhibitor and preparation method thereof and purposes |
CN109336863A (en) * | 2018-10-04 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | A kind of novel phthalazines ketone BTK inhibitor, preparation and its application |
CN109180643A (en) * | 2018-10-04 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | Phthalazines ketone compound crystal form A and preparation method thereof |
CA3141748A1 (en) * | 2019-06-10 | 2020-12-17 | Lupin Limited | Prmt5 inhibitors |
CN110305140B (en) * | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | Dihydropyrrolopyrimidines selective JAK2 inhibitors |
AU2020405446A1 (en) | 2019-12-20 | 2022-05-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
JP2023519603A (en) | 2020-03-31 | 2023-05-11 | ヌエヴォリューション・アクティーゼルスカブ | Compounds active against nuclear receptors |
AU2021249530A1 (en) | 2020-03-31 | 2022-12-01 | Nuevolution A/S | Compounds active towards nuclear receptors |
US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
EP2258371A1 (en) * | 2001-08-10 | 2010-12-08 | Novartis AG | Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia |
DE60225316T2 (en) | 2001-11-13 | 2009-02-26 | AXYS Pharmaceuticals, Inc., South San Francisco | CYANO ALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS |
US20060183746A1 (en) * | 2003-06-04 | 2006-08-17 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
CN101124227A (en) * | 2004-11-10 | 2008-02-13 | Cgi制药有限公司 | Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity |
ES2337831T3 (en) | 2005-06-24 | 2010-04-29 | Bristol-Myers Squibb Company | USEFUL PHENYLGLYCINAMIDE AND PIRIDYLCLYCINAMIDE DERIVATIVES |
EP1940843A4 (en) * | 2005-08-11 | 2010-09-15 | Ariad Pharma Inc | Unsaturated heterocyclic derivatives |
AU2006284900A1 (en) | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3, 5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-receptor tyrosine kinases |
US20070129364A1 (en) | 2005-12-07 | 2007-06-07 | Han-Qing Dong | Pyrrolopyridine kinase inhibiting compounds |
JP5442448B2 (en) | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | Bicyclic heterocyclic compounds as FGFR inhibitors |
US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
NZ586916A (en) | 2008-02-05 | 2012-06-29 | Hoffmann La Roche | Novel pyridinones and pyridazinones |
US8507501B2 (en) | 2008-03-13 | 2013-08-13 | The Brigham And Women's Hospital, Inc. | Inhibitors of the BMP signaling pathway |
US8501765B2 (en) | 2008-06-11 | 2013-08-06 | Genentech, Inc. | Diazacarbazoles and methods of use |
PE20110164A1 (en) | 2008-07-02 | 2011-03-28 | Hoffmann La Roche | NEW PHENYLpyRAZINONES AS KINASE INHIBITORS |
WO2010003133A2 (en) | 2008-07-03 | 2010-01-07 | Exelixis Inc. | Cdk modulators |
EP2321274A1 (en) | 2008-07-08 | 2011-05-18 | Boehringer Ingelheim International GmbH | Pyrrolidinyl and piperidinyl compounds useful as nhe-1 inhibitors |
UY31984A (en) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | DERIVATIVES OF N-substituted 1- (3,4-difluorobenzyl) -6-oxo-1,6-dihydropyrimidin-5-carboxamides and 2- (3,4-difluorobenzyl) -3-oxo-2,3-dihydro- N-substituted 1H-pyrazol-4-carboxamides. |
KR101358532B1 (en) | 2008-07-18 | 2014-02-05 | 에프. 호프만-라 로슈 아게 | Novel phenylimidazopyrazines |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
WO2010068806A1 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer |
WO2010068810A2 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
WO2010068788A1 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Heterocyclic amides as btk inhibitors |
US8084620B2 (en) | 2008-12-19 | 2011-12-27 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
ES2513915T3 (en) | 2009-04-24 | 2014-10-27 | F. Hoffmann-La Roche Ag | Bruton Tyrosine Kinase Inhibitors |
US8586751B2 (en) | 2009-06-12 | 2013-11-19 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
EP2464647B1 (en) | 2009-08-11 | 2016-09-21 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
HUE043522T2 (en) * | 2009-09-04 | 2019-08-28 | Biogen Ma Inc | Bruton's tyrosine kinase inhibitors |
US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
KR101906791B1 (en) | 2010-01-27 | 2018-10-11 | 베링거 인겔하임 인터내셔날 게엠베하 | Pyrazole compounds as crth2 antagonists |
WO2012136343A1 (en) * | 2011-04-05 | 2012-10-11 | Eth Zurich | Droplet dispensing device and light source comprising such a droplet dispensing device |
ES2548414T3 (en) * | 2011-07-08 | 2015-10-16 | Novartis Ag | Novel pyrimidine pyrrolo derivatives |
EP2744804B1 (en) | 2011-08-17 | 2017-05-17 | F. Hoffmann-La Roche AG | Inhibitors of bruton's tyrosine kinase |
-
2013
- 2013-04-18 CN CN201380019452.8A patent/CN104662018B/en not_active Expired - Fee Related
- 2013-04-18 EP EP13737672.9A patent/EP2838898B1/en active Active
- 2013-04-18 AU AU2013250726A patent/AU2013250726B2/en not_active Ceased
- 2013-04-18 JP JP2015506355A patent/JP6182593B2/en active Active
- 2013-04-18 CA CA2869954A patent/CA2869954C/en active Active
- 2013-04-18 IN IN1573CH2012 patent/IN2012CH01573A/en unknown
- 2013-04-18 WO PCT/IN2013/000259 patent/WO2013157022A1/en active Application Filing
-
2014
- 2014-10-08 US US14/509,793 patent/US9233983B2/en active Active
- 2014-10-09 ZA ZA2014/07341A patent/ZA201407341B/en unknown
- 2014-10-19 IL IL235146A patent/IL235146A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2869954A1 (en) | 2013-10-24 |
WO2013157022A1 (en) | 2013-10-24 |
JP6182593B2 (en) | 2017-08-16 |
EP2838898B1 (en) | 2017-01-18 |
IL235146A (en) | 2017-07-31 |
ZA201407341B (en) | 2015-06-24 |
CN104662018A (en) | 2015-05-27 |
US9233983B2 (en) | 2016-01-12 |
AU2013250726B2 (en) | 2017-01-05 |
JP2015514749A (en) | 2015-05-21 |
US20150064196A1 (en) | 2015-03-05 |
CN104662018B (en) | 2017-10-24 |
EP2838898A1 (en) | 2015-02-25 |
CA2869954C (en) | 2023-01-03 |
AU2013250726A1 (en) | 2014-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012CH01573A (en) | ||
MX2013012983A (en) | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity. | |
PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
IN2015DN02008A (en) | ||
PH12016501440A1 (en) | Novel heterocyclic compounds | |
AU2011325657B2 (en) | Novel 6-arylamino pyridone carboxamide as MEK inhibitors | |
PH12015500488A1 (en) | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
MX2018003008A (en) | Pyrazolyl-substituted heteroaryls and their use as medicaments. | |
MX2015001715A (en) | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases. | |
EA201492250A1 (en) | Heterocyclic Compound | |
MX345170B (en) | Inhibitors of bruton's tyrosine kinase. | |
NZ629432A (en) | Heterocyclyl compounds as mek inhibitors | |
MY143483A (en) | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders | |
EA201592033A1 (en) | 3- (2-AMINOPYRIMIDIN-4-IL) -5- (3-HYDROXYPROPYNYL) -1H-PYRROLO [2,3-c] PyRIDINE DERIVATIVES AS NIK INHIBITORS FOR CANCER TREATMENT | |
NZ601267A (en) | Fused heteroaromatic pyrrolidinones as syk inhibitors | |
MX2013012776A (en) | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors. | |
MX2014001653A (en) | Inhibitors of bruton's tyrosine kinase. | |
WO2014172513A3 (en) | 3,5-(un)substituted-1h-pyrrolo[2,3-b]pyridine, 1h-pyrazolo[3,4-b]pyridine and 5h-pyrrolo [2-,3-b]pyrazine dual itk and jak3 kinase inhibitors | |
IN2014DN07885A (en) | ||
WO2014093230A3 (en) | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity | |
EA201700042A1 (en) | IMIDAZOPIRIDAZIN CONNECTIONS | |
TN2016000511A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
EA201600636A1 (en) | 2-AMINO-6-METHYL-4,4A, 5,6-TETRAHYDROPYRANO [3,4-D] [1,3] TIASIN-8A (8H) -IL-1,3-TIAZOL-4-IL AMIDY | |
MX2015010983A (en) | Inhibitors of bruton's tyrosine kinase. | |
NZ589314A (en) | Diamino-pyrimidine-5-carboxamide compounds as inhibitors of Spleen tyrosine kinase (syk) and JAK kinases |